Developer docs
API playgroundTry for free, no card

Search company profiles

Cabaletta Bio

Full company profile

uuid00021wo

Namestring
Cabaletta Bio
Legal namestring
Cabaletta Bio, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. The company's proprietary CABA (Cabaletta Approach to B cell Ablation) platform supports the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy, with lead candidate rese-cel (resecabtagene autoleucel) — a fully human CD19-CAR T cell therapy with a 4-1BB co-stimulatory domain designed as a one-time infusion that transiently depletes B cells to enable durable, potentially curative drug-free remission. Rese-cel is being evaluated across five RESET Phase 1/2 clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris, with 52+ evaluable patients dosed and an 83% immunomodulator-free response rate observed in dermatomyositis.

The company has no approved products and generates no product revenue. Its operating model centers on advancing clinical trials at major US academic medical centers, securing FDA designations (five Fast Track, four RMAT, one Rare Pediatric Disease), and building a commercial supply chain through a 10-year commercial agreement with Cellares for automated manufacturing on the Cell Shuttle platform — the first cell therapy manufacturing technology to receive FDA Advanced Manufacturing Technology designation. R&D spending reached $142.7M in FY2025 and the company reported a Q1 2026 net loss of $43.5M.

Cabaletta is preparing for its first BLA submission for rese-cel in myositis in the second half of 2027, with systemic sclerosis designated as the second pivotal indication (registrational study expected to begin Q4 2026). The company is publicly traded on NASDAQ (CABA), headquartered in Philadelphia, and was founded in 2017 emerging from the University of Pennsylvania. It has raised approximately $337M in public offerings since 2023, including a $150M registered direct offering in May 2026 with participation from Bain Capital Life Sciences, Eli Lilly, Cormorant Asset Management, and Adage Capital, extending cash runway into mid-2027.

Short descriptiontext

Cabaletta Bio is a clinical-stage biotechnology company developing rese-cel, a fully human CD19-CAR T cell therapy, to treat B cell-mediated autoimmune diseases including lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris through five RESET Phase 1/2 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR T cell therapy, autoimmune disease therapy, engineered T cell therapies, B cell ablation, cell therapy platform
Industry5 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy for Autoimmune Diseases
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue / Clinical Stage
TypeOne Time License
Description

Cabaletta Bio is a clinical-stage biotechnology company with no commercialized products. The company has no reported product revenue. All revenue generation is expected upon FDA approval and commercial launch of rese-cel, anticipated beginning with a BLA submission in myositis in 2027.

cabalettabio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1No commercial pricing available — investigational therapy in clinical trials
ModelOtherBilling cadenceOther
Notes

Cabaletta Bio has no approved products. Rese-cel is an investigational therapy evaluated in clinical trials at no cost to participants. Future commercial pricing has not been disclosed.

cabalettabio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cabaletta Bio is developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its lead product, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy with a 4-1BB co-stimulatory domain designed as a one-time infusion to transiently deplete B cells and potentially reset the immune system. The therapy is being evaluated across multiple Phase 1/2 RESET clinical trials in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, with automated manufacturing via Cellares Cell Shuttle under a 10-year commercial supply agreement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 83% (5/6) of dermatomyositis patients achieved immunomodulator-free moderate-to-major TIS response at 16 weeks vs. 50% registrational threshold requirement
+5 more records
Product overview1 text field

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. The company's core offering centers on rese-cel (resecabtagene autoleucel), a fully human CD19-CAR T cell therapy with 4-1BB co-stimulatory domain, built on the proprietary CABA platform. Rese-cel is being evaluated across five RESET Phase 1/2 clinical trials in multiple autoimmune indications: myositis (RESET-Myositis), systemic lupus erythematosus (RESET-SLE), systemic sclerosis (RESET-SSc), generalized myasthenia gravis (RESET-MG), and pemphigus vulgaris (RESET-PV). Manufacturing is supported by a 10-year commercial supply agreement with Cellares using their automated Cell Shuttle platform. The company is planning its first BLA submission for rese-cel in myositis in 2027.

Product and service7 records
1Rese-cel (resecabtagene autoleucel)
CategoryCore product / investigational cell therapy
Description

Investigational fully human CD19 chimeric antigen receptor (CAR) T cell therapy with a 4-1BB co-stimulatory domain designed to transiently eliminate B cells, potentially enabling an immune system reset for patients with autoimmune diseases. Administered as a one-time infusion.

2RESET-Myositis Phase 1/2 Trial
CategoryClinical trial
Description

Phase 1/2 clinical trial evaluating rese-cel in patients with idiopathic inflammatory myopathies, including dermatomyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy. Includes juvenile myositis cohort. 83% of DM patients achieved immunomodulator-free TIS response.

3RESET-SLE Phase 1/2 Trial
CategoryClinical trial
Description

Phase 1/2 clinical trial evaluating rese-cel in patients with systemic lupus erythematosus and lupus nephritis. 75% of patients with 12 months follow-up achieved DORIS remission while remaining off immunomodulators.

4RESET-SSc Phase 1/2 Trial
CategoryClinical trial
Description

Phase 1/2 clinical trial evaluating rese-cel in patients with systemic sclerosis, including those with interstitial lung disease. 83% (5/6) achieved rCRISS-25 and 67% (4/6) achieved rCRISS-50 at 36 weeks while off immunomodulators.

5RESET-MG Phase 1/2 Trial
CategoryClinical trial
Description

Phase 1/2 clinical trial evaluating rese-cel in patients with generalized myasthenia gravis, including both AChR-positive and AChR-negative patients. 5 AChR-positive and 5 AChR-negative patients experienced clinically meaningful improvement on MG-ADL score.

6RESET-PV Phase 1/2 Trial
CategoryClinical trial
Description

Phase 1/2 clinical trial evaluating rese-cel without lymphodepleting preconditioning in patients with pemphigus vulgaris. Preliminary data shows complete B cell depletion and early clinical responses without standard preconditioning regimen.

7Cellares Cell Shuttle Manufacturing Platform (for rese-cel production)
CategoryManufacturing platform / commercial supply
Description

Automated cell therapy manufacturing platform used for commercial-scale production of rese-cel under a 10-year commercial supply agreement, enabling scalable, low-cost manufacturing with reduced manual touchpoints. First FDA Advanced Manufacturing Technology designation for cell therapy.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCore / FlagshipTypeTechnology or IntegrationAnnounced on2026-04-28
Description

Cabaletta Bio signed a 10-year commercial supply agreement with Cellares in April 2026 for the automated manufacture of rese-cel using Cellares' Cell Shuttle™ and Cell Q™ platforms. This partnership enables flexible, low-cost scaling of commercial production to thousands of batches per year at among the lowest cost per batch in the industry. The collaboration builds on prior work since 2023, including successful first patient dosing with GMP-grade rese-cel manufactured on the automated platform in April 2026.

Strategic tierCore / FlagshipTypeTechnology or IntegrationAnnounced on2023-01-01
Description

Ongoing manufacturing partnership with Cellares, the first Integrated Development and Manufacturing Organization (IDMO). Cellares received FDA Advanced Manufacturing Technology designation for its Cell Shuttle platform — the first cell therapy manufacturing technology to achieve this. The companies have collaborated since 2023 to adapt the rese-cel manufacturing process to the automated platform, with FDA clearance obtained for clinical manufacturing use.

Strategic tierFoundational / CoreTypeStrategic or Co-development Partner
Description

Cabaletta Bio originated from the University of Pennsylvania in 2017. The company was founded by leading Penn experts in autoimmune diseases and CAR T technology (including Dr. Aimee Payne and Dr. Michael Milone, co-inventors of CTL019/tisagenlecleucel). The company continues to collaborate with Penn on clinical trials and research. Dr. Carl June (Penn) serves on Cabaletta's Scientific Advisory Board.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHOP is listed as a clinical collaborator. Dr. Catherine Bollard (Children's National Health System / George Washington University) serves on Cabaletta's Board of Directors.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

UC Davis is listed as both a scientific and clinical collaborator for Cabaletta Bio's programs.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Yale University is listed as a scientific collaborator for Cabaletta Bio's research programs.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Stanford Medicine is listed as a clinical collaborator for Cabaletta Bio's autoimmune disease programs.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

The University of Iowa is listed as a clinical collaborator for Cabaletta Bio's autoimmune disease programs.

Strategic tierSupportingTypeTechnology or Integration
Description

Artisan Bio is listed as an industry partner for Cabaletta Bio's cell therapy development programs.

10B-MoGen Biotechnologies
Strategic tierSupportingTypeTechnology or Integration
Description

B-MoGen Biotechnologies is listed as an industry partner for Cabaletta Bio's cell therapy development programs.

cabalettabio.com
Strategic tierSupportingTypeTechnology or Integration
Description

WuXi AppTec is listed as an industry partner providing contract manufacturing and development services for Cabaletta Bio's cell therapy programs.

Strategic tierSupportingTypeTechnology or Integration
Description

Oxford BioMedica is listed as an industry partner for Cabaletta Bio's cell therapy development programs.

Strategic tierSupportingTypeOthers
Description

The Lupus Foundation of America is listed as an advocacy partner helping connect Cabaletta Bio with the lupus patient community.

14International Pemphigus and Pemphigoid Foundation (IPPF)
Strategic tierSupportingTypeOthers
Description

The International Pemphigus and Pemphigoid Foundation is listed as an advocacy partner helping connect Cabaletta Bio with the pemphigus vulgaris patient community.

cabalettabio.com
Strategic tierSupportingTypeOthers
Description

The Myasthenia Gravis Foundation of America is listed as an advocacy partner helping connect Cabaletta Bio with the myasthenia gravis patient community.

Strategic tierSupportingTypeOthers
Description

Cure JM Foundation is listed as an advocacy partner helping connect Cabaletta Bio with the juvenile myositis patient community.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing KYV-101, an autologous CD19 CAR-T cell therapy for autoimmune diseases including lupus, myositis, and other B cell-mediated conditions — the most directly competitive program to Cabaletta's rese-cel with overlapping indications and trial designs.

2Bristol Myers Squibb
TypeBroad incumbent
Description

Major pharmaceutical company with Breyanzi (lisocabtagene maraleucel), an approved CD19 CAR-T therapy originally for lymphoma that is now being investigated in autoimmune diseases; also sells approved lupus therapies (Saphnelo) that compete for the same autoimmune patients Cabaletta is targeting.

TypeBroad incumbent
Description

Owns Kite Pharma, a leading cell therapy franchise with approved CD19 CAR-T therapies (Yescarta, Tecartus). Has the largest commercial CAR-T infrastructure and is positioned to extend into autoimmune indications where rese-cel will compete for patients and treatment center capacity.

TypeBroad incumbent
Description

Developed and commercializes Kymriah (tisagenlecleucel), the first FDA-approved CAR-T therapy, originally partnered with the University of Pennsylvania where Cabaletta's founders trained. Novartis has the deepest CAR-T commercial experience globally and could enter autoimmune indications through label expansion.

5Johnson & Johnson / Legend Biotech
TypeBroad incumbent
Description

Co-develop and commercialize Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T for multiple myeloma. Legend Biotech's commercial leadership previously included Steve Gavel (now Cabaletta's CCO), and J&J's pharma scale makes them a natural competitor if they pursue autoimmune CAR-T indications.

TypeEmerging player
Description

Clinical-stage biotech developing allogeneic gamma delta CAR-T cell therapies for autoimmune diseases and oncology. Its off-the-shelf approach, if successful, would compete directly with Cabaletta's autologous rese-cel on convenience, cost, and scalability.

TypeEmerging player
Description

Clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR-based genome editing for both oncology and autoimmune indications. Its allogeneic platform is a direct alternative approach to rese-cel's autologous model in overlapping autoimmune diseases.

TypeEmerging player
Description

Clinical-stage biotech pioneering allogeneic CAR-T cell therapies for oncology and autoimmune diseases, with CD19 and CD70 programs in development. Its allogeneic manufacturing model would compete with rese-cel on cost and time-to-treatment.

TypeOthers
Description

Cell therapy company that helped bring three cell therapy products to approval (Abecma, and others via bluebird bio heritage). Cabaletta's CTO Sarah Yuan previously led process and analytical development at 2seventy bio, making it a comparable technical and CMC organization.

TypeEmerging player
Description

Clinical-stage biotech developing off-the-shelf iPSC-derived cell therapies, including NK and T cell products for autoimmune and oncology indications. Its multiplexed-engineering, off-the-shelf approach is an alternative platform paradigm to Cabaletta's autologous CAR-T model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cabaletta Bio

Cell Therapy for Autoimmune Diseasescabalettabio.com

Cabaletta Bio is a clinical-stage biotechnology company developing rese-cel, a fully human CD19-CAR T cell therapy, to treat B cell-mediated autoimmune diseases including lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris through five RESET Phase 1/2 trials.

What Cabaletta Bio does

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. The company's proprietary CABA (Cabaletta Approach to B cell Ablation) platform supports the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy, with lead candidate rese-cel (resecabtagene autoleucel) — a fully human CD19-CAR T cell therapy with a 4-1BB co-stimulatory domain designed as a one-time infusion that transiently depletes B cells to enable durable, potentially curative drug-free remission. Rese-cel is being evaluated across five RESET Phase 1/2 clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris, with 52+ evaluable patients dosed and an 83% immunomodulator-free response rate observed in dermatomyositis.

The company has no approved products and generates no product revenue. Its operating model centers on advancing clinical trials at major US academic medical centers, securing FDA designations (five Fast Track, four RMAT, one Rare Pediatric Disease), and building a commercial supply chain through a 10-year commercial agreement with Cellares for automated manufacturing on the Cell Shuttle platform — the first cell therapy manufacturing technology to receive FDA Advanced Manufacturing Technology designation. R&D spending reached $142.7M in FY2025 and the company reported a Q1 2026 net loss of $43.5M.

Cabaletta is preparing for its first BLA submission for rese-cel in myositis in the second half of 2027, with systemic sclerosis designated as the second pivotal indication (registrational study expected to begin Q4 2026). The company is publicly traded on NASDAQ (CABA), headquartered in Philadelphia, and was founded in 2017 emerging from the University of Pennsylvania. It has raised approximately $337M in public offerings since 2023, including a $150M registered direct offering in May 2026 with participation from Bain Capital Life Sciences, Eli Lilly, Cormorant Asset Management, and Adage Capital, extending cash runway into mid-2027.

Cabaletta Bio firmographics

Firmographics
Name
Cabaletta Bio
Legal name
Cabaletta Bio, Inc.
Website
https://cabalettabio.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Cabaletta Bio is a clinical-stage biotechnology company developing rese-cel, a fully human CD19-CAR T cell therapy, to treat B cell-mediated autoimmune diseases including lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris through five RESET Phase 1/2 trials.
Ownership category
akta.pro rank

Cabaletta Bio industry classification

Industry
Product category
Cell Therapy for Autoimmune Diseases
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • CAR T cell therapy
  • Autoimmune disease therapy
  • Engineered T cell therapies
  • B cell ablation
  • Cell therapy platform

Where Cabaletta Bio is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cabaletta Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-Revenue / Clinical Stage: Cabaletta Bio is a clinical-stage biotechnology company with no commercialized products. The company has no reported product revenue. All revenue generation is expected upon FDA approval and commercial launch of rese-cel, anticipated beginning with a BLA submission in myositis in 2027.

Pricing tiers

ModelBillingPrice
OtherOtherNo commercial pricing available — investigational therapy in clinical trials

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Cabaletta Bio product offering

Product offering

Core offering

Cabaletta Bio is developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its lead product, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy with a 4-1BB co-stimulatory domain designed as a one-time infusion to transiently deplete B cells and potentially reset the immune system. The therapy is being evaluated across multiple Phase 1/2 RESET clinical trials in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, with automated manufacturing via Cellares Cell Shuttle under a 10-year commercial supply agreement.

Product overview

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. The company's core offering centers on rese-cel (resecabtagene autoleucel), a fully human CD19-CAR T cell therapy with 4-1BB co-stimulatory domain, built on the proprietary CABA platform. Rese-cel is being evaluated across five RESET Phase 1/2 clinical trials in multiple autoimmune indications: myositis (RESET-Myositis), systemic lupus erythematosus (RESET-SLE), systemic sclerosis (RESET-SSc), generalized myasthenia gravis (RESET-MG), and pemphigus vulgaris (RESET-PV). Manufacturing is supported by a 10-year commercial supply agreement with Cellares using their automated Cell Shuttle platform. The company is planning its first BLA submission for rese-cel in myositis in 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rese-cel (resecabtagene autoleucel) Investigational fully human CD19 chimeric antigen receptor (CAR) T cell therapy with a 4-1BB co-stimulatory domain designed to transiently eliminate B cells, potentially enabling an immune system reset for patients with autoimmune diseases. Administered as a one-time infusion.
  • RESET-Myositis Phase 1/2 Trial Phase 1/2 clinical trial evaluating rese-cel in patients with idiopathic inflammatory myopathies, including dermatomyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy. Includes juvenile myositis cohort. 83% of DM patients achieved immunomodulator-free TIS response.
  • RESET-SLE Phase 1/2 Trial Phase 1/2 clinical trial evaluating rese-cel in patients with systemic lupus erythematosus and lupus nephritis. 75% of patients with 12 months follow-up achieved DORIS remission while remaining off immunomodulators.
  • RESET-SSc Phase 1/2 Trial Phase 1/2 clinical trial evaluating rese-cel in patients with systemic sclerosis, including those with interstitial lung disease. 83% (5/6) achieved rCRISS-25 and 67% (4/6) achieved rCRISS-50 at 36 weeks while off immunomodulators.
  • RESET-MG Phase 1/2 Trial Phase 1/2 clinical trial evaluating rese-cel in patients with generalized myasthenia gravis, including both AChR-positive and AChR-negative patients. 5 AChR-positive and 5 AChR-negative patients experienced clinically meaningful improvement on MG-ADL score.
  • RESET-PV Phase 1/2 Trial Phase 1/2 clinical trial evaluating rese-cel without lymphodepleting preconditioning in patients with pemphigus vulgaris. Preliminary data shows complete B cell depletion and early clinical responses without standard preconditioning regimen.
  • Cellares Cell Shuttle Manufacturing Platform (for rese-cel production) Automated cell therapy manufacturing platform used for commercial-scale production of rese-cel under a 10-year commercial supply agreement, enabling scalable, low-cost manufacturing with reduced manual touchpoints. First FDA Advanced Manufacturing Technology designation for cell therapy.

Quantifiable outcome

  • 83% (5/6) of dermatomyositis patients achieved immunomodulator-free moderate-to-major TIS response at 16 weeks vs. 50% registrational threshold requirement
  • +5 more outcomes

Companies that use Cabaletta Bio

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Cabaletta Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cabaletta Bio partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core / flagship, foundational / core, core and supporting.

  • Cellarescore / flagshipTechnology or Integration · 28 April 2026Cabaletta Bio signed a 10-year commercial supply agreement with Cellares in April 2026 for the automated manufacture of rese-cel using Cellares' Cell Shuttle™ and Cell Q™ platforms. This partnership enables flexible, low-cost scaling of commercial production to thousands of batches per year at among the lowest cost per batch in the industry. The collaboration builds on prior work since 2023, including successful first patient dosing with GMP-grade rese-cel manufactured on the automated platform in April 2026.
  • Cellares (Manufacturing Technology)core / flagshipTechnology or Integration · 1 January 2023Ongoing manufacturing partnership with Cellares, the first Integrated Development and Manufacturing Organization (IDMO). Cellares received FDA Advanced Manufacturing Technology designation for its Cell Shuttle platform — the first cell therapy manufacturing technology to achieve this. The companies have collaborated since 2023 to adapt the rese-cel manufacturing process to the automated platform, with FDA clearance obtained for clinical manufacturing use.
  • University of Pennsylvaniafoundational / coreStrategic or Co-development PartnerCabaletta Bio originated from the University of Pennsylvania in 2017. The company was founded by leading Penn experts in autoimmune diseases and CAR T technology (including Dr. Aimee Payne and Dr. Michael Milone, co-inventors of CTL019/tisagenlecleucel). The company continues to collaborate with Penn on clinical trials and research. Dr. Carl June (Penn) serves on Cabaletta's Scientific Advisory Board.
  • Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development PartnerCHOP is listed as a clinical collaborator. Dr. Catherine Bollard (Children's National Health System / George Washington University) serves on Cabaletta's Board of Directors.
  • UC DavissupportingStrategic or Co-development PartnerUC Davis is listed as both a scientific and clinical collaborator for Cabaletta Bio's programs.
  • Yale UniversitysupportingStrategic or Co-development PartnerYale University is listed as a scientific collaborator for Cabaletta Bio's research programs.
  • Stanford MedicinesupportingStrategic or Co-development PartnerStanford Medicine is listed as a clinical collaborator for Cabaletta Bio's autoimmune disease programs.
  • The University of IowasupportingStrategic or Co-development PartnerThe University of Iowa is listed as a clinical collaborator for Cabaletta Bio's autoimmune disease programs.
  • Artisan BiosupportingTechnology or IntegrationArtisan Bio is listed as an industry partner for Cabaletta Bio's cell therapy development programs.
  • B-MoGen BiotechnologiessupportingTechnology or IntegrationB-MoGen Biotechnologies is listed as an industry partner for Cabaletta Bio's cell therapy development programs.
  • WuXi AppTecsupportingTechnology or IntegrationWuXi AppTec is listed as an industry partner providing contract manufacturing and development services for Cabaletta Bio's cell therapy programs.
  • Oxford BioMedicasupportingTechnology or IntegrationOxford BioMedica is listed as an industry partner for Cabaletta Bio's cell therapy development programs.
  • Lupus Foundation of AmericasupportingOthersThe Lupus Foundation of America is listed as an advocacy partner helping connect Cabaletta Bio with the lupus patient community.
  • International Pemphigus and Pemphigoid Foundation (IPPF)supportingOthersThe International Pemphigus and Pemphigoid Foundation is listed as an advocacy partner helping connect Cabaletta Bio with the pemphigus vulgaris patient community.
  • Myasthenia Gravis Foundation of America (MGFA)supportingOthersThe Myasthenia Gravis Foundation of America is listed as an advocacy partner helping connect Cabaletta Bio with the myasthenia gravis patient community.
  • Cure JM FoundationsupportingOthersCure JM Foundation is listed as an advocacy partner helping connect Cabaletta Bio with the juvenile myositis patient community.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Cabaletta Bio competitors and assessment

Company assessment

Direct peers

  • Kyverna Therapeutics: Clinical-stage biotech developing KYV-101, an autologous CD19 CAR-T cell therapy for autoimmune diseases including lupus, myositis, and other B cell-mediated conditions — the most directly competitive program to Cabaletta's rese-cel with overlapping indications and trial designs.

Broad incumbents

  • Bristol Myers Squibb: Major pharmaceutical company with Breyanzi (lisocabtagene maraleucel), an approved CD19 CAR-T therapy originally for lymphoma that is now being investigated in autoimmune diseases; also sells approved lupus therapies (Saphnelo) that compete for the same autoimmune patients Cabaletta is targeting.
  • Gilead Sciences (Kite): Owns Kite Pharma, a leading cell therapy franchise with approved CD19 CAR-T therapies (Yescarta, Tecartus). Has the largest commercial CAR-T infrastructure and is positioned to extend into autoimmune indications where rese-cel will compete for patients and treatment center capacity.
  • Novartis: Developed and commercializes Kymriah (tisagenlecleucel), the first FDA-approved CAR-T therapy, originally partnered with the University of Pennsylvania where Cabaletta's founders trained. Novartis has the deepest CAR-T commercial experience globally and could enter autoimmune indications through label expansion.
  • Johnson & Johnson / Legend Biotech: Co-develop and commercialize Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T for multiple myeloma. Legend Biotech's commercial leadership previously included Steve Gavel (now Cabaletta's CCO), and J&J's pharma scale makes them a natural competitor if they pursue autoimmune CAR-T indications.

Emerging players

  • Adicet Bio: Clinical-stage biotech developing allogeneic gamma delta CAR-T cell therapies for autoimmune diseases and oncology. Its off-the-shelf approach, if successful, would compete directly with Cabaletta's autologous rese-cel on convenience, cost, and scalability.
  • Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR-based genome editing for both oncology and autoimmune indications. Its allogeneic platform is a direct alternative approach to rese-cel's autologous model in overlapping autoimmune diseases.
  • Allogene Therapeutics: Clinical-stage biotech pioneering allogeneic CAR-T cell therapies for oncology and autoimmune diseases, with CD19 and CD70 programs in development. Its allogeneic manufacturing model would compete with rese-cel on cost and time-to-treatment.
  • Fate Therapeutics: Clinical-stage biotech developing off-the-shelf iPSC-derived cell therapies, including NK and T cell products for autoimmune and oncology indications. Its multiplexed-engineering, off-the-shelf approach is an alternative platform paradigm to Cabaletta's autologous CAR-T model.

Others

  • 2seventy bio: Cell therapy company that helped bring three cell therapy products to approval (Abecma, and others via bluebird bio heritage). Cabaletta's CTO Sarah Yuan previously led process and analytical development at 2seventy bio, making it a comparable technical and CMC organization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

Cabaletta Bio social profiles

Digital presence

Cabaletta Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cabaletta Bio leadership team

Management profile

Number of profiles

Profiles11 records

Cabaletta Bio funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cabaletta Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cabaletta Bio

What does Cabaletta Bio do?

Cabaletta Bio is developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its lead product, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy with a 4-1BB co-stimulatory domain designed as a one-time infusion to transiently deplete B cells and potentially reset the immune system. The therapy is being evaluated across multiple Phase 1/2 RESET clinical trials in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris, with automated manufacturing via Cellares Cell Shuttle under a 10-year commercial supply agreement.

Is Cabaletta Bio a public or private company?

Cabaletta Bio is a public company. It is classified as public and is currently operating.

When was Cabaletta Bio founded?

Cabaletta Bio was founded in 2017. It employs 101 to 250 people.

Where is Cabaletta Bio based?

Cabaletta Bio is headquartered in Philadelphia, United States, in the North America region.

How does Cabaletta Bio make money?

One revenue line is on record: pre-Revenue / Clinical Stage.

Who are Cabaletta Bio's main competitors?

Kyverna Therapeutics is listed as a direct peer. Broad incumbents are Bristol Myers Squibb, Gilead Sciences (Kite), Novartis and Johnson & Johnson / Legend Biotech. Emerging players are Adicet Bio, Caribou Biosciences, Allogene Therapeutics and Fate Therapeutics. 2seventy bio is listed as an others.

Does Cabaletta Bio have an API?

No public API is recorded for Cabaletta Bio.

What industry is Cabaletta Bio in?

Cabaletta Bio's product category is Cell Therapy for Autoimmune Diseases. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StCabaletta Bio (CABA) Stock Looks Undervalued Even After Fresh Trial DataCabaletta Bio's shares have fallen about 92.9% over three years, yet new Phase 1/2 data for rese-cel in autoimmune diseases has renewed investor interest. The stock trades at a P/B of 1.0x, below the biotech sector average of 1.8x, suggesting it is priced as more asset-backed than peers.The future of tradingCabaletta Bio presents rese-cel data showing sustained one-year responses in all six adult dermatomyositis patientsCabaletta Bio presented rese-cel data showing all six adult dermatomyositis patients maintained immunomodulator-free moderate-to-major responses through one year, with 67% steroid-free. Safety data from 71 patients showed 94% had no cytokine release syndrome or grade 1 events, and 96% had no neurotoxicity syndrome. The company expects registrational RESET-Myositis topline results in the second half of 2027.The future of tradingCabaletta Bio Reports One-Year Rese-cel Responses in All Six Dermatomyositis Patients in Phase 1/2 StudyCabaletta Bio reported Phase 1/2 rese-cel results for dermatomyositis patients, showing one-year responses in all six patients without immunomodulators. Safety data from 71 patients showed mostly absent or mild cytokine release syndrome and no treatment-associated neurotoxicity. Registrational adult myositis results are expected in the second half of 2027, with a biologics application planned for early 2028.American Banking and Market NewsCabaletta Bio (NASDAQ:CABA) Raised to Sell at Wall Street ZenWall Street Zen upgraded Cabaletta Bio from a strong sell to a sell rating. The stock opened at $1.30, with an average analyst rating of Moderate Buy and a consensus target price of $15.60. The company reported a loss of $0.28 per share for the quarter, beating estimates.TradingViewCabaletta Bio Reports Q3 2026 Results, $299.4 Million Cash PositionCabaletta Bio reported a Q3 2026 net loss of $53.1 million and a cash position of $299.4 million as of September 30. The company expects its cash to fund operations into the first quarter of 2028, with myositis topline results anticipated in the second half of 2027.Business & FinancialCabaletta Bio To Participate In Upcoming Investor ConferencesCabaletta Bio will participate in Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026, and Jefferies' Global Healthcare Conference in London on November 18, 2026. The company's lead product candidate, rese-cel, is a 4-1BB-containing CD19-CAR T cell therapy for autoimmune diseases.MarketBeatCabaletta Bio, Inc. (NASDAQ:CABA) Stock Has Average Price Target of $15.60 According to AnalystsCabaletta Bio shares have an average analyst rating of Moderate Buy with a 12-month price target of $15.60. The stock opened at $1.58, up 4.3%, and the company reported a quarterly loss of $0.34 per share, beating estimates. Analysts expect a current-year loss of $1.34 per share.American Banking and Market NewsCabaletta Bio, Inc. (NASDAQ:CABA) Stock Has Consensus Price Target of $15.60 According to BrokeragesCabaletta Bio's stock has an average analyst price target of $15.60 with a Moderate Buy consensus. The company reported Q2 EPS of -$0.34, beating the -$0.37 consensus, and analysts forecast -$1.34 EPS for the fiscal year. Several hedge funds increased their stakes in the biotech firm.MarketBeatCabaletta Bio (NASDAQ:CABA) Stock Gets Downgrade from Wall Street ZenWall Street Zen downgraded Cabaletta Bio from a sell to a strong sell rating. The stock opened at $1.41, with a consensus Moderate Buy rating and average price target of $15.60. Analysts expect a fiscal-year EPS of -$1.34.American Banking and Market NewsCabaletta Bio (NASDAQ:CABA) Stock Rating Cut to “Strong Sell” at Wall Street ZenWall Street Zen downgraded Cabaletta Bio to a strong sell rating, while TD Cowen, HC Wainwright, and William Blair upgraded to strong buy. The stock opened at $1.41, with a consensus Moderate Buy and average target of $15.60. The company reported a loss of $0.34 per share for the quarter.